Amir Hossein Barjasteh*, Mostafa Saebi, Mahmoud Mahmoudi, Ramiar Kamal Kheder, Seyed Isaac Hashemy, Fatemeh Forouzanfar and Seyed-Alireza Esmaeili* Pages 1020 - 1036 ( 17 )
Cancer is a significant health challenge worldwide, causing social and economic burdens. Despite advancements in medicine, it remains a leading cause of death and is projected to increase by 2040. While conventional treatments like surgery, radiation, and chemotherapy are effective, they often have severe side effects. CAR T-cell (chimeric antigen receptor T-cell) treatment is a novel immunotherapy method personalized to the patient's immune system and directly targets cancer cells. It originated in the 1980s, and advancements have made it more effective. However, challenges remain, such as severe side effects, high costs, and manufacturing variability. Despite these challenges, the treatment with CAR T-cells has shown remarkable success, especially in hematologic malignancies. Though, it is new to solid tumours, ongoing research looks promising. CAR T-cell therapy offers hope for fightingcancer, and it stands poised to redefine cancer treatment paradigms, giving renewed optimism to patients globally.
Cancer treatment, CAR T-cell, immunotherapy, malignancy, tumour, oncology.